Vaccine science: immunization schedules, herd immunity calculation, vaccine hesitancy

Intuition Beginner

Vaccines have saved more lives than any intervention except clean water. In 1796 Edward Jenner noticed milkmaids who caught cowpox never caught smallpox; he inoculated a boy with cowpox and proved him immune. Smallpox became the only human disease ever eradicated (1980). A vaccine trains the immune system with a weakened or fragmented pathogen, building memory cells that react within hours when the real threat appears. Herd immunity — when enough people are immune that transmission chains collapse — shields those who cannot be vaccinated: newborns, the immunocompromised. Measles demands ~95% coverage because each case infects roughly fifteen others (R0 ≈ 15). Vaccine hesitancy, fuelled by Andrew Wakefield's fraudulent 1998 study linking vaccines to autism, remains a top-ten WHO threat.

Visual Beginner

The diagram pairs three ideas. First, the platforms differ in how they deliver antigen but converge on one goal: a memory population that recognises the pathogen. Live attenuated vaccines replicate, giving the strongest and most durable immunity but ruling out immunocompromised recipients; mRNA and subunit vaccines trade intensity for safety and manufacturability.

Second, the middle panel distinguishes the naive from the memory response: a first encounter produces antibody after one to two weeks, while a second encounter produces a faster, higher, and higher-affinity response — the immunological basis for booster doses.

Third, the right panel turns individual protection into population protection. Re falls with coverage and crosses one at the herd-immunity threshold; above it, each case infects fewer than one other person on average, so outbreaks die out. Measles sits high on the curve (threshold near 95%) and influenza low (near 33%), which is why measles outbreaks follow even small drops in uptake. The threshold climbs further when the vaccine is imperfect.

Worked example Beginner

Worked example: why measles needs 95% coverage

Measles is among the most contagious diseases: in a fully susceptible population each case infects about fifteen others, so R0 is approximately 15. The herd-immunity threshold is 1 - 1/R0 = 1 - 1/15, about 0.93 — 93% of the population must be immune to interrupt transmission.

Because a single measles-mumps-rubella dose is only about 93% effective, a second dose is required, and two doses reach about 97% effectiveness. Allowing for imperfect effectiveness and pockets of refusal, the operational target rises to 95%. Below it, the susceptible fraction exceeds 7%, and a single imported case can ignite an outbreak.

This is not hypothetical: the 2014-15 Disneyland outbreak spread through under-vaccinated clusters in California, leading the state to end non-medical exemptions in 2015 (SB 277). The arithmetic shows why mandates, not just recommendations, are often the deciding factor.

Check your understanding Beginner

Question 1: The idealised herd-immunity threshold for a disease with R0 = 3 (original COVID-19) is closest to:

A) 33%
B) 50%
C) 67%
D) 95%

Answer: C. Threshold = 1 − 1/3 ≈ 0.67.

Question 2: True or false: Andrew Wakefield's 1998 Lancet study linking MMR to autism was retracted, and its author was struck off the UK medical register.

Answer: True. The paper was retracted in 2010 and the General Medical Council removed Wakefield from practice.

Question 3: Which vaccine type is generally NOT recommended for severely immunocompromised patients?

A) Inactivated (Salk polio)
B) Subunit (HPV)
C) Toxoid (tetanus)
D) Live attenuated (MMR)

Answer: D. Live attenuated vaccines can replicate and cause disease in hosts with severely impaired immunity.

Question 4: The critical vaccine coverage needed for herd immunity rises when:

A) R0 falls
B) vaccine efficacy is below 100%
C) overall coverage increases
D) the pathogen becomes less transmissible

Answer: B. Imperfect efficacy inflates the required coverage: $p_c=(1-1/R_0)/e$.

Formal definition Intermediate+

Vaccine platforms and the antigen they present

Vaccines are classified by how the antigen reaches the immune system. Live attenuated vaccines (MMR, varicella, yellow fever, oral polio) replicate within the host, producing the strongest and most durable immunity; they are contraindicated in severe immunodeficiency. Inactivated vaccines (Salk polio, rabies, hepatitis A) cannot replicate and are safer but weaker, often requiring boosters. Subunit, conjugate, and recombinant vaccines (Hib, pneumococcal, HPV, hepatitis B) present only selected antigens, improving safety. Toxoid vaccines (tetanus, diphtheria) neutralise bacterial toxins rather than the organism. Viral-vector vaccines (Ebola, J&J COVID) use a harmless adenovirus to deliver genetic code for the antigen. mRNA vaccines (Pfizer-BioNTech, Moderna) deliver lipid-nanoparticle-encapsulated messenger RNA coding for the spike protein, which host cells translate before degrading the message (see 33.06.* double helix; 35.02.03 viral pathogenesis). Each platform trades immunogenicity against safety, stability, and scalability; the nontrivial engineering choice is platform-specific.

Correlates of protection and immunological memory

Adaptive immunity rests on B cells (which make antibodies) and T cells (which coordinate and kill), and on the memory cells that persist after the antigen clears (see 17.10.* immunology). A correlate of protection is a measurable immune marker — usually neutralising-antibody titre — that predicts clinical protection; Plotkin established the framework for identifying such correlates. The primary response to a first dose is slow and modest; affinity maturation in germinal centres refines B-cell receptors over weeks. A booster dose re-encounters antigen and elicits a faster, larger, and higher-affinity response, the immunological justification for multi-dose schedules (see 29.02.04 neuroplasticity for an analogy to neural memory). Adjuvants — aluminium salts, MF59, AS04, and Toll-like-receptor agonists — amplify the response by activating innate immunity and presenting pathogen-associated molecular patterns (see 35.02.02 bacterial pathogenesis, PAMPs).

Herd immunity: thresholds and effective reproduction

The basic reproduction number $R_0$ is the expected cases generated by one infected individual in a fully susceptible population. The idealised herd-immunity threshold is $H=1-1/R_0$. For measles ($R_0\approx 12\text{–}18$) $H\approx 92\text{–}95\%$; for polio ($R_0\approx 5\text{–}7$) $H\approx 80\text{–}85\%$; for COVID-19 ($R_0\approx 3$) $H\approx 67\%$; for influenza ($R_0\approx 1.5$) $H\approx 33\%$. With a vaccine of efficacy $e$ administered to coverage $p$, the effectively immune fraction is $p\cdot e$ and the effective reproduction number is $R_e=R_0(1-p\cdot e)$; $R_e<1$ is the control condition (see 35.02.03 SIR model; 37.05.* probability, Markov chains).

Immunization schedules

Schedules orchestrate doses by age, immune maturity, and epidemiology. The CDC schedule spans birth (hepatitis B) through 18 years, with catch-up pathways for late starters (see 35.06.01 public health). Adult immunisation covers influenza, pneumococcal disease, shingles, and Tdap boosters; pregnancy adds Tdap, influenza, and RSV vaccines, the last protecting newborns through maternal antibodies (see 35.03.* chronic disease, pregnancy). Travel vaccines — yellow fever, typhoid, Japanese encephalitis — match regional risk. The WHO publishes country-by-country position papers and schedules; alignment between national schedules is an ongoing logistical challenge for global immunisation.

Vaccine development and surveillance

New vaccines move through Phase I (safety), II (immunogenicity and dose), and III (efficacy) randomised trials (see 29.01.02 psychology research methods, RCT; 35.02.04 epidemiology). Emergency Use Authorisation during COVID-19 compressed this timeline through overlapping trials and manufacturing-at-risk, underwritten by Operation Warp Speed (see 33.08.* big science). Post-marketing surveillance continues indefinitely: passive systems (VAERS) collect spontaneous reports while active systems (CDC's Vaccine Safety Datalink) query electronic records — the discipline of pharmacovigilance (see 35.07.* pharmacology). Rare adverse events at one-in-a-million frequency can be detected only after millions of doses, which is why surveillance, not pre-licensure trials, often finds them.

Vaccine hesitancy: the 3 Cs

The WHO SAGE working group defines vaccine hesitancy as a delay in acceptance or refusal despite availability, structured by three drivers: Complacency (perceived low risk), Convenience (access, cost, time), and Confidence (trust in vaccine, provider, and policy). Omer showed that exemptors cluster geographically, creating susceptible pockets where outbreaks ignite (see 35.02.03 SIR model). The most damaging confidence shock was Wakefield's 1998 Lancet paper falsely linking MMR to autism — retracted in 2010, its author struck off by the UK General Medical Council (see 29.01.03 statistical reasoning, replication crisis; 36.* media literacy). Parental decision-making reflects affective and social factors as much as evidence (see 29.05.02 decision-making; 29.07.* social psychology), and during COVID-19 these attitudes aligned sharply with political identity (see 30.07.* social movements).

Key theorem with proof Intermediate+

Key result: critical coverage under imperfect vaccines

Claim. When a vaccine has efficacy $e$ ($0<e\le 1$), the critical coverage required for herd immunity is $p_c=(1-1/R_0)/e$, which strictly exceeds the idealised threshold $1-1/R_0$ whenever $e<1$.

Derivation. Model the population in two states: a fraction $p$ is vaccinated, of whom a fraction $e$ is fully protected, leaving $1-p\cdot e$ effectively susceptible. A typical infective generates $R_0$ new cases scaled by the susceptible fraction, giving the effective reproduction number $R_e=R_0(1-p\cdot e)$. An epidemic cannot grow when $R_e<1$. Solving $R_0(1-p\cdot e)<1$ for $p$ yields $p\cdot e>1-1/R_0$, hence $p>(1-1/R_0)/e$. When $e=1$ the result collapses to the familiar $H=1-1/R_0$; when $e<1$ the required coverage inflates by the factor $1/e$.

Numerical illustration. For measles ($R_0=15$) and two-dose efficacy $e=0.97$, $p_c=(1-1/15)/0.97\approx 0.96$, i.e. ~96% — operationally rounded to the 95% target cited above. For COVID-19 ($R_0=3$) and $e=0.9$, $p_c\approx 0.74$. The theorem formalises an intuition: no vaccine is perfectly effective, so herd immunity is harder to reach than the textbook formula suggests, and coverage gaps magnify as efficacy falls.

Exercises Intermediate+

1. A disease has $R_0=5$ and a vaccine of efficacy $e=0.8$. Compute the idealised threshold $H$ and the critical coverage $p_c$. Why does $p_c$ exceed $H$, and what does the value of $p_c$ imply about eliminating this disease through vaccination alone?

2. Measles $R_0$ ranges 12–18. Report the idealised herd-immunity threshold for each extreme, and explain why the operational target is set at the high end.

3. A Phase III trial randomises 30,000 participants evenly between vaccine and placebo. There are 8 symptomatic cases in the vaccine arm and 162 in the placebo arm. Compute vaccine efficacy, and explain why high efficacy alone does not guarantee herd immunity.

4. A region reports 88% MMR coverage. Using $R_0=15$ and two-dose efficacy $0.97$, estimate $R_e$. Is the region protected, and what coverage would be required?

5. Using the 3 Cs model, propose two distinct interventions to raise uptake, and predict which type of hesitancy each addresses.

6. Contrast the immunological justification for booster doses with the epidemiological justification. Why does a highly efficacious vaccine still require boosters?

7. A passive-surveillance system reports a rare adverse event at higher frequency after a new vaccine than background. Give three reasons this signal might be confounded before concluding causation.

Advanced results Master

Vaccine history: from variolation to eradication

Immunisation predates microbiology. Variolation — inoculating healthy people with material from smallpox pustules — was practised in China, India, and the Ottoman Empire, and was introduced to England by Lady Mary Wortley Montagu after observing it in Constantinople (see 32.10.* Islamic Golden Age). In 1796 Edward Jenner replaced this dangerous procedure with cowpox inoculation, naming it "vaccination" from vacca, Latin for cow. Pasteur extended the principle to rabies (1885) and anthrax using artificially attenuated organisms, founding modern immunology (see 33.04.* chemistry revolution). The twentieth century brought the Salk (injected) and Sabin (oral) polio vaccines, funded by the March of Dimes, and the WHO smallpox eradication campaign led by D. A. Henderson, which declared success in 1980 — the only deliberate eradication of a human pathogen (see 33.08.* big science; 35.06.* public health triumph). Measles neared elimination before resurging as the anti-vaccine movement grew (see 35.02.04 epidemiology).

COVID-19 and the mRNA platform

The pandemic compressed a thirty-year research programme into a twelve-month product. Katalin Karikó and Drew Weissman discovered in 2005 that modifying messenger RNA nucleosides suppressed innate-immune rejection, the enabling insight for lipid-nanoparticle delivery (see 33.06.* double helix). The Pfizer-BioNTech (BNT162b2) and Moderna (mRNA-1273) vaccines entered Phase III trials within ten months of pathogen identification and reported ~95% efficacy against symptomatic disease (see 35.02.03 viral pathogenesis). Viral-vector competitors (Oxford-AstraZeneca ChAdOx1, Johnson & Johnson Ad26) used adenovirus backbones. The response exposed deep inequities: COVAX struggled against vaccine nationalism, and patent-waiver debates reprised long-running disputes over access to essential medicines (see 30.07.03 global inequality; 31.06.* anthropology, global health; 36.* media literacy for misinformation around VAERS data).

Cancer vaccines: prevention and therapy

Two licensed vaccines prevent cancer by blocking oncogenic viruses. Hepatitis B vaccination, introduced in 1981, was the first anti-cancer vaccine, preventing hepatocellular carcinoma; HPV vaccines (Gardasil) prevent the cervical and oropharyngeal cancers caused by high-risk human papillomavirus strains (see 35.03.03 cancer biology, viral oncogenesis; 35.02.03 viral pathogenesis). Therapeutic cancer vaccines aim to stimulate T-cell responses against a patient's own tumour neoantigens. Personalised mRNA neoantigen vaccines, now in trials for melanoma and pancreatic cancer, sequence a tumour, predict immunogenic mutations, and manufacture a bespoke mRNA construct — converging cancer immunotherapy (35.03.03) with genomic medicine (35.08.02) and mRNA technology (33.06.*).

The pipeline: HIV, malaria, influenza, tuberculosis

Decades of effort have not produced an HIV vaccine: the virus's antigenic diversity, integration into the host genome, and rapid mutation outpace classical design (see 29.09.03 anxiety/trauma, HIV; 35.02.03 antigenic variation). RTS,S/Mosquirix, the first malaria vaccine, received WHO endorsement in 2021 after a century of attempts (see 35.06.* public health, tropical disease). BCG, the tuberculosis vaccine, is a century old and only partially effective; next-generation candidates target the latent infection BCG misses (see 35.02.02 bacterial pathogenesis). A universal influenza vaccine targeting the conserved haemagglutinin stalk, rather than the variable head, would remove the need for annual reformulation (see 35.02.03 antigenic variation). Plant-based (Medicago) and thermostable oral platforms address cold-chain limits in low-income settings (see 32.18.* industrial revolution, biotechnology; 31.06.* anthropology).

Vaccines and society: mandates, compensation, and trust

Vaccination raises the classical tension between individual autonomy and collective security. California's SB277 (2015) and SB276 (2019) eliminated non-medical exemptions after measles outbreaks; the ethics tracks the harm principle (see 20.02.08 deontology; 20.07.* democracy, public-health law). The US National Vaccine Injury Compensation Program, established in 1986, offers no-fault compensation to preserve both safety monitoring and manufacturer participation (see 30.06.* deviance, tort law). Social-media platforms now mediate vaccine confidence at scale, and influencer-driven misinformation during COVID-19 reframed vaccination as a partisan identity marker (see 36.* media literacy; 30.02.03 media-culture-industry). Globally, Gavi, the Vaccine Alliance, and the Gates Foundation have expanded routine immunisation to hundreds of millions of children, exemplifying twenty-first-century philanthropic governance (see 33.08.* big science; 31.06.* global health governance).

Connections Master

Immunology and infectious disease (see 17.10., 35.02.)

Adaptive immunity, B and T cells, and memory are the biological substrate of vaccination (17.10.*); bacterial (35.02.02) and viral (35.02.03) pathogenesis supply the antigens vaccines target, and epidemiology (35.02.04) supplies the threshold arithmetic that this unit extends to imperfect vaccines.

Probability and statistics (see 37.05., 29.01.)

Vaccine efficacy is a relative-risk calculation grounded in probability (37.05.*), and the clinical-trial machinery that establishes efficacy is the same randomised design used across the empirical sciences (29.01.02); the replication crisis (29.01.03) frames how the Wakefield fraud persisted despite overwhelming contrary evidence.

Ethics and political philosophy (see 20.02., 20.07.)

Mandates, exemptions, and no-fault compensation raise deontological and democratic questions about autonomy, coercion, and the common good. The classical warrant is Mill's harm principle: foregoing vaccination in a high-$R_0$ disease harms others by eroding herd immunity.

Sociology and anthropology (see 30.04., 31.06.)

Clustered refusal is a sociological phenomenon of networks and identity (30.04.), and global immunisation equity is a question of structural violence and global health governance (31.06.) — Farmer's preferential option for the poor applied to vaccine access.

Psychology and media literacy (see 29.05., 29.07., 36.*)

Hesitancy reflects affective decision-making (29.05.02) and group identity (29.07.), amplified by platform-mediated misinformation (36.). The asymmetry between the speed of a rumour and the speed of correction is now a core problem of public-health communication.

Molecular biology and big science (see 33.06., 33.08.)

The mRNA platform is a product of the molecular-biology revolution (33.06.), and its deployment was a big-science mobilisation (33.08.) rivaling the Apollo programme in coordination, speed, and public investment.

Historical and philosophical context Master

Jenner, variolation, and the Ottoman connection

Variolation reached Western Europe through Lady Mary Wortley Montagu, who observed it in the Ottoman court in 1717 and inoculated her own children. The practice cut smallpox mortality roughly tenfold but could itself transmit disease. Jenner's 1796 experiment — transferring cowpox from a milkmaid's lesion to eight-year-old James Phipps, then challenging him with smallpox — showed that an animal virus could safely cross-protect. Jenner could not explain the mechanism; he operated a century before viruses were defined. The episode illustrates how empirical craft can outrun theory, and how colonial exchange transmitted medical technique as well as pathogens (see 32.10.* Islamic Golden Age).

Pasteur and the laboratory vaccine

Louis Pasteur converted vaccination from empirical craft into laboratory science. His anthrax vaccine (1881) and rabies vaccine (1885) used artificially attenuated pathogens, deliberately weakened rather than discovered in nature. The rabies vaccine, given to nine-year-old Joseph Meister after a rabid-dog bite, made vaccination a public event and Pasteur an international hero. His work linked immunisation to the germ theory of disease and to the broader chemistry and microbiology revolution of the nineteenth century (see 33.04.* chemistry revolution).

Salk, Sabin, and the March of Dimes

Polio terrified mid-century America. Jonas Salk's inactivated vaccine, licensed in 1955 after the largest clinical trial in history, was funded by public donations through the March of Dimes — a model of citizen-funded medical research. Albert Sabin's oral attenuated vaccine followed in 1961, easier to administer and better at interrupting transmission, and became the workhorse of the global eradication effort. The Salk–Sabin rivalry, and the Cutter incident (in which one manufacturer's faulty inactivation caused polio in children), shaped modern vaccine regulation and post-marketing surveillance.

Smallpox: the only eradication

The WHO smallpox eradication campaign, led by D. A. Henderson from 1966, combined mass vaccination with ring vaccination around outbreaks, a strategy made feasible by the virus's lack of an animal reservoir and its visible symptoms. The last natural case occurred in Somalia in 1977; the World Health Assembly declared eradication in 1980. It remains the only deliberate eradication of a human pathogen, a public-health triumph that established both the possibility and the difficulty of eradication as a goal — polio remains tantalisingly close yet unfinished (see 35.06.* public health).

The Wakefield affair and the cost of fraud

Andrew Wakefield's 1998 Lancet paper, alleging that MMR caused autism and bowel disease, was based on twelve children, undisclosed financial conflicts, and ethical violations. Investigative journalism exposed the fraud; the paper was retracted in 2010 and the UK General Medical Council struck Wakefield off the register. But the damage persisted: uptake fell, measles returned to endemic status in the UK, and the autism–vaccine myth became unkillable in online networks. The episode is a case study in how a single retracted paper can outweigh thousands of well-conducted studies in public perception, and in the asymmetry between the speed of misinformation and the speed of correction (see 29.01.03 statistical reasoning; 36.* media literacy).

Autonomy, community, and the ethics of mandates

Mandatory vaccination sets individual liberty against the protection of those who cannot protect themselves — infants, the immunocompromised, and the small fraction for whom vaccination fails. John Stuart Mill's harm principle provides the classical warrant: the state may coerce when the act harms others, and foregoing vaccination in a high-$R_0$ disease does harm others by eroding herd immunity. Opponents invoke bodily autonomy and the right to refuse medical treatment. The practical question is not whether to coerce but how — school-entry requirements, workplace mandates, incentives, or nudges — and how to maintain trust while doing so. No framework dissolves the tension; the nontrivial task is designing policy that preserves both protection and consent.

Bibliography Master

1. Plotkin, S. A., Orenstein, W. A., Offit, P. A., & Edwards, K. M. (Eds.). (2023). Vaccines (8th ed.). Elsevier. ^{[source pending]}

2. World Health Organization. (2024). Immunization Schedules by Vaccine, Brand Name and Number of Doses (WHO vaccine position papers). ^{[source pending]}

3. Omer, S. B., Salmon, D. A., Orenstein, W. A., deHart, M. P., & Halsey, N. (2009). "Vaccine Refusal, Mandatory Immunization, and the Risks of Vaccine-Preventable Diseases." New England Journal of Medicine, 360(19), 1981–1988. ^{[source pending]}

4. Offit, P. A. (2008). Autism's False Prophets: Bad Science, Risky Medicine, and the Search for a Cure. Columbia University Press. ^{[source pending]}

5. Plotkin, S. A. (2008). "Correlates of Vaccine-Induced Immunity." Clinical Infectious Diseases, 47(3), 401–409.

6. Karikó, K., Buckstein, M., Ni, H., & Weissman, D. (2005). "Suppression of RNA Recognition by Toll-like Receptors: The Impact of Nucleoside Modification and the Evolutionary Origin of RNA." Immunity, 23(2), 165–175.

7. Jenner, E. (1798). An Inquiry into the Causes and Effects of the Variolae Vaccinae. Sampson Low.

8. Henderson, D. A. (2009). Smallpox: The Death of a Disease — The Inside Story of Eradicating a Worldwide Killer. Prometheus.

9. Polack, F. P., Thomas, S. J., Kitchin, N., et al. (2020). "Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine." New England Journal of Medicine, 383(27), 2603–2615.

10. MacDonald, N. E., & the SAGE Working Group on Vaccine Hesitancy. (2015). "Vaccine hesitancy: Definition, scope and determinants." Vaccine, 33(34), 4161–4164.

11. Wakefield, A. J., et al. (1998). [RETRACTED] "Ileal-lymphoid-nodular hyperplasia, non-specific colitis, and pervasive developmental disorder in children." The Lancet, 351(9103), 637–641.

12. Feikin, D. R., Lezotte, D. C., Hamman, R. F., Salmon, D. A., Chen, R. T., & Hoffman, R. E. (2000). "Individual and Community Risks of Measles and Pertussis Associated with Personal Exemptions to Immunization." JAMA, 284(24), 3145–3150.

13. Roush, S. W., & Murphy, T. V. (2007). "Historical Comparisons of Morbidity and Mortality for Vaccine-Preventable Diseases in the United States." JAMA, 298(18), 2155–2163.